甘精胰岛素联合瑞格列奈对2型糖尿病患者血糖控制及低血糖发生率的影响  

Impact of Insulin Glargine Combined with Repaglinide on the Blood Glucose Control and Incidence of Hypoglycemia in Patients with Type 2 Diabetes

作　　者：李叶莉[1] LI Yeli(Department of Endocrinology,Huizhou First People's Hospital,Huizhou 516300,China)

机构地区：[1]惠州市第一人民医院内分泌科,广东惠州516300

出　　处：《临床医学工程》2021年第2期201-202,共2页Clinical Medicine & Engineering

摘　　要：目的探讨甘精胰岛素联合瑞格列奈对2型糖尿病患者血糖控制以及低血糖发生率的影响。方法选取2型糖尿病患者70例,随机分为两组各35例。对照组予以甘精胰岛素治疗,实验组予以甘精胰岛素联合瑞格列奈治疗,两组均治疗3个月。比较两组的血糖控制及低血糖发生率。结果治疗后,两组的FPG、2hPG与HbA1c水平均显著低于治疗前,且实验组的各指标水平均显著低于对照组(P<0.05)。治疗期间,实验组的低血糖发生率为5.71%,显著低于对照组的22.86%(P<0.05)。结论甘精胰岛素联合瑞格列奈治疗2型糖尿病能有效控制患者的血糖在目标范围,稳定病情,降低低血糖发生率。Objective To explore the impact of insulin glargine combined with repaglinide on the blood glucose control and incidence of hypoglycemia in patients with type 2 diabetes.Methods 70 patients with type 2 diabetes were selected and randomly divided into two groups,with 35 cases in each group.The control group was treated with insulin glargine,and the experimental group was treated with insulin glargine combined with repaglinide.Both groups were treated for 3 months.The blood glucose control and the incidence of hypoglycemia were compared between the two groups.Results After treatment,the levels of FPG,2 hPG and HbA1 c in both groups were significantly lower than those before treatment,and the levels of FPG,2 hPG and HbA1 c of experimental group were significantly lower than those of control group(P<0.05).During treatment,the incidence of hypoglycemia of experimental group was 5.71%,significantly lower than 22.86%of control group(P<0.05).Conclusions Insulin glargine combined with repaglinide in the treatment of type 2 diabetes can effectively control patients’blood glucose in the target range,stabilize disease condition,and reduce the incidence of hypoglycemia.

关 键 词：甘精胰岛素 瑞格列奈 2型糖尿病 血糖控制 低血糖 

分 类 号：R587.1[医药卫生—内分泌]